Posters Archive - Scholar Rock https://scholarrock.com/posters/ Thu, 07 Nov 2024 14:00:22 +0000 en-US hourly 1 https://wordpress.org/?v=6.7.1 https://scholarrock.com/wp-content/uploads/2020/08/cropped-favicon-32x32.png Posters Archive - Scholar Rock https://scholarrock.com/posters/ 32 32 DRAGON trial: durable remission rate with the latent TGFβ1 inhibitor linavonkibart (SRK-181) and pembrolizumab in patients with immune checkpoint inhibitor–resistant advanced cancers https://scholarrock.com/posters/dragon-trial-durable-remission-rate-with-the-latent-tgf%ce%b21-inhibitor-linavonkibart-srk-181-and-pembrolizumab-in-patients-with-immune-checkpoint-inhibitor-resistant-advanced-cancers/ Thu, 07 Nov 2024 14:00:00 +0000 https://scholarrock.com/?post_type=poster&p=1203 The post DRAGON trial: durable remission rate with the latent TGFβ1 inhibitor linavonkibart (SRK-181) and pembrolizumab in patients with immune checkpoint inhibitor–resistant advanced cancers appeared first on Scholar Rock.

]]> The post DRAGON trial: durable remission rate with the latent TGFβ1 inhibitor linavonkibart (SRK-181) and pembrolizumab in patients with immune checkpoint inhibitor–resistant advanced cancers appeared first on Scholar Rock.

]]> SRK-439 Selectively Inhibits Myostatin to Promote Healthy Body Composition During Metformin Therapy https://scholarrock.com/posters/srk-439-selectively-inhibits-myostatin-to-promote-healthy-body-composition-during-metformin-therapy/ Mon, 04 Nov 2024 13:00:00 +0000 https://scholarrock.com/?post_type=poster&p=1201 The post SRK-439 Selectively Inhibits Myostatin to Promote Healthy Body Composition During Metformin Therapy appeared first on Scholar Rock.

]]> The post SRK-439 Selectively Inhibits Myostatin to Promote Healthy Body Composition During Metformin Therapy appeared first on Scholar Rock.

]]> Longer-term efficacy, safety, and patient-reported outcomes of apitegromab in patients with nonambulatory SMA: Results from the 48-month TOPAZ study https://scholarrock.com/posters/longer-term-efficacy-safety-and-patient-reported-outcomes-of-apitegromab-in-patients-with-nonambulatory-sma-results-from-the-48-month-topaz-study/ Fri, 11 Oct 2024 19:40:43 +0000 https://scholarrock.com/?post_type=poster&p=1196 The post Longer-term efficacy, safety, and patient-reported outcomes of apitegromab in patients with nonambulatory SMA: Results from the 48-month TOPAZ study appeared first on Scholar Rock.

]]> The post Longer-term efficacy, safety, and patient-reported outcomes of apitegromab in patients with nonambulatory SMA: Results from the 48-month TOPAZ study appeared first on Scholar Rock.

]]> Apitegromab in spinal muscular atrophy: Baseline characteristics of participants enrolled in the phase 3 SAPPHIRE study https://scholarrock.com/posters/apitegromab-in-spinal-muscular-atrophy-baseline-characteristics-of-participants-enrolled-in-the-phase-3-sapphire-study/ Fri, 11 Oct 2024 19:39:14 +0000 https://scholarrock.com/?post_type=poster&p=1194 The post Apitegromab in spinal muscular atrophy: Baseline characteristics of participants enrolled in the phase 3 SAPPHIRE study appeared first on Scholar Rock.

]]> The post Apitegromab in spinal muscular atrophy: Baseline characteristics of participants enrolled in the phase 3 SAPPHIRE study appeared first on Scholar Rock.

]]> The Anti-Myostatin Antibody SRK-439 Promotes Healthy Body Composition in Combination with GLP-1RAs in a Mouse Model of Obesity https://scholarrock.com/posters/the-anti-myostatin-antibody-srk-439-promotes-healthy-body-composition-in-combination-with-glp-1ras-in-a-mouse-model-of-obesity/ Mon, 24 Jun 2024 10:59:35 +0000 https://scholarrock.com/?post_type=poster&p=1182 The post The Anti-Myostatin Antibody SRK-439 Promotes Healthy Body Composition in Combination with GLP-1RAs in a Mouse Model of Obesity appeared first on Scholar Rock.

]]> The post The Anti-Myostatin Antibody SRK-439 Promotes Healthy Body Composition in Combination with GLP-1RAs in a Mouse Model of Obesity appeared first on Scholar Rock.

]]> An Update on Scholar Rock’s Progress in SMA https://scholarrock.com/posters/an-update-on-scholar-rocks-progress-in-sma/ Wed, 12 Jun 2024 19:50:47 +0000 https://scholarrock.com/?post_type=poster&p=1179 The post An Update on Scholar Rock’s Progress in SMA appeared first on Scholar Rock.

]]> The post An Update on Scholar Rock’s Progress in SMA appeared first on Scholar Rock.

]]> Phase1 study (DRAGON) of SRK-181 (linavonkibart), a latent TGFβ1inhibitor, combined with pembrolizumab in anti-PD1 resistant patients with advanced solid tumors: Updated results of expansion phase https://scholarrock.com/posters/phase1-study-dragon-of-srk-181-linavonkibart-a-latent-tgf%ce%b21inhibitor-combined-with-pembrolizumab-in-anti-pd1-resistant-patients-with-advanced-solid-tumors-updated-results-of-expansion-phas/ Mon, 03 Jun 2024 20:00:17 +0000 https://scholarrock.com/?post_type=poster&p=1175 The post Phase1 study (DRAGON) of SRK-181 (linavonkibart), a latent TGFβ1inhibitor, combined with pembrolizumab in anti-PD1 resistant patients with advanced solid tumors: Updated results of expansion phase appeared first on Scholar Rock.

]]> The post Phase1 study (DRAGON) of SRK-181 (linavonkibart), a latent TGFβ1inhibitor, combined with pembrolizumab in anti-PD1 resistant patients with advanced solid tumors: Updated results of expansion phase appeared first on Scholar Rock.

]]> Effect Of Apitegromab on Motor Function and Patient-reported Outcomes at 36 Months in Patients Aged 2–21 Years with Spinal Muscular Atrophy https://scholarrock.com/posters/effect-of-apitegromab-on-motor-function-and-patient-reported-outcomes-at-36-months-in-patients-aged-2-21-years-with-spinal-muscular-atrophy-2/ Sat, 23 Mar 2024 21:15:00 +0000 https://scholarrock.com/?post_type=poster&p=1171 The post Effect Of Apitegromab on Motor Function and Patient-reported Outcomes at 36 Months in Patients Aged 2–21 Years with Spinal Muscular Atrophy appeared first on Scholar Rock.

]]> The post Effect Of Apitegromab on Motor Function and Patient-reported Outcomes at 36 Months in Patients Aged 2–21 Years with Spinal Muscular Atrophy appeared first on Scholar Rock.

]]> Disease Burden in Patients with Spinal Muscular Atrophy (SMA) Treated with Survival Motor Neuron (SMN)-Targeted Therapies: A Targeted Literature Review https://scholarrock.com/posters/disease-burden-in-patients-with-spinal-muscular-atrophy-sma-treated-with-survival-motor-neuron-smn-targeted-therapies-a-targeted-literature-review/ Mon, 04 Mar 2024 19:33:48 +0000 https://scholarrock.com/?post_type=poster&p=1165 The post Disease Burden in Patients with Spinal Muscular Atrophy (SMA) Treated with Survival Motor Neuron (SMN)-Targeted Therapies: A Targeted Literature Review appeared first on Scholar Rock.

]]> The post Disease Burden in Patients with Spinal Muscular Atrophy (SMA) Treated with Survival Motor Neuron (SMN)-Targeted Therapies: A Targeted Literature Review appeared first on Scholar Rock.

]]> Effect of apitegromab on motor function and patient-reported outcomes at 36 months in patients aged 2–21 years with spinal muscular atrophy https://scholarrock.com/posters/effect-of-apitegromab-on-motor-function-and-patient-reported-outcomes-at-36-months-in-patients-aged-2-21-years-with-spinal-muscular-atrophy/ Mon, 04 Mar 2024 19:02:19 +0000 https://scholarrock.com/?post_type=poster&p=1166 The post Effect of apitegromab on motor function and patient-reported outcomes at 36 months in patients aged 2–21 years with spinal muscular atrophy appeared first on Scholar Rock.

]]> The post Effect of apitegromab on motor function and patient-reported outcomes at 36 months in patients aged 2–21 years with spinal muscular atrophy appeared first on Scholar Rock.

]]>